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A B S T R A C T
Dry eye, due to its impaired function of tear film becomes more susceptible to all
kinds of airborne allergens. Due to air pollution this is more marked in urban areas,
and is compounded by the modern way of life. There are various standard topical medi-
cations which alleviate allergic reaction of the eye, but many of them must be adminis-
tered with caution and only on short term due to their potentially hazardous side effects.
The purpose of this work is to assess the efficacy of lodoxamide, a new antiallergic medi-
cation for topical use, whose advantage is low or absent risk of adverse side effects, in al-
leviating local allergic reactions of the eye in patients with dry eye. Research has shown
that, compared to treatment with eye lubricants alone (artificial tears), treatment with
artificial tears combined with lodoxamide has resulted in more marked decrease in the
signs of inflammation, and to the lesser extent to the reduction of the symptoms as well.
Introduction
Dry eye, due to its impaired function
of tear film, becomes more susceptible to
external irritants, such are pollens, envi-
ronmental airborne pollutants in cities,
dust mites etc. Schein et al. (1997) esti-
mates that 4.3 million Americans age
65–84 suffer from periodic or permanent
symptoms of eye irritation1. Using tear
break up time (TBUT) as diagnostic crite-
ria, McCarty et al. (1998) have diagnosed
dry eye in 8.6% of Melbourne citizens
older than 402. In Canadian optometry
practices, Doughty et al. (1997) have
found 28.7% of patients complaining of
dry eye symptoms in age group 10–80, al-
though only 7.8% had »moderate but per-
manent symptoms« 3. In Croatia, author’s
experience shows that 6,3% of all pa-
tients seen in his practice in September
and November 1998 had symptoms and
signs of dry eye4. Toda et al. (1995) have
shown in their work that allergic conjunc-
tivitis might be the cause of decrease of
goblet cell density, what directly affects
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TBUT5. This allergic component of pa-
tient’s symptoms might be alleviated by
the application of antiallergic topical eye
medication. Currently available topical
antiallergic eye medications include cor-
ticosteroids, antihistamines, NSAID’s,
and medications with the combined ef-
fect. Corticosteroids are potent, but their
potentially serious side effects make
them risky medications for the long-term
use. Antihistamines frequently lack effi-
cacy, while NSAID eye medications also
have side effects similar to those of cor-
ticosteroids. lodoxamide 0,1% ophthalmic
solution (Alomide, ALCON) affects several
stages of allergic response: it stabilizes
mast cells, inhibits eosinophil migration
and inhibits allergic reaction mediators
release6. Perhaps the most significant ad-
vantage for the clinical use of lodoxamide
is its safety in long term application, with
no known serious side effects.
The purpose of this study is to assess
the possibility of use of lodoxamide 0.1%
eye drops as an adjuvant therapy for pa-
tients with the chronic eye irritation cau-
sed by the dry eye, in order to alleviate
their symptoms and improve their life
quality.
Patients and Methods
In period between January 26 and
June 30, 2000, at the Outpatient Depart-
ment of Eye Clinic »Rebro«, University of
Zagreb, 44 patients were included in this
study. None of the patients were previ-
ously treated with the same medications,
nor examined by the study researcher.
Patients’ age was 25–87 (mean 57). 82%
of the patients were women. Inclusion
criteria was chronic eye irritation, with-
out any pronounced eye inflammation
symptoms or infectious disease history.
Patients were randomly divided into two
groups: in group A, 23 patients were
treated with standard lubricant therapy
(artificial tears sid + eye lubricant gel in
the evening). In group B, 21 patient was
treated with the same medications with
the addition of lodoxamide 0.1% eye drops
(Alomide ALCON) qid. Analyzed parame-
ters included subjective symptoms and ob-
jective signs. Subjective symptoms were:
foreign body sensation, itching, irritation
more pronounced in the morning, irrita-
tion more pronounced by the wind, irrita-
tion more pronounced by watching TV or
computer work and irritation more pro-
nounced by cold weather. Objective signs
related to tear dysfunction that were ana-
lyzed included tear break-up time (TBUT),
conjunctivae hyperemia, 6 o’clock punctu-
ate keratitis and blepharitis. To every pa-
rameter a score from 0 to 3 was assigned,
3 being the most pronounced symptom or
sign. TBUT was assessed as follows: 0 =
longer than 10 sec; 1 = 10–7 sec; 2 = 6–3
sec; 3 = 2–0 sec. Above mentioned param-
eters were evaluated twice: upon enroll-
ment in study and at the check-up visit
2–3 weeks later.
Results
The sign that was most pronounced in
virtually every patient with long term eye
irritation was drastically reduced TBUT.
On assessment before treatment, 73% of
the patients in group A and 70% of pa-
tients in group B had TBUT 2 sec or lower.
After therapy, patients’ symptoms sco-
re improved in groups A and B by 52%
and 58% respectively (Figure 1). There
was 8% signs score improvement in group
A, as opposed to 32% in Graph 1 Improve-
ment of symptoms after therapy (percent-
age)group B (Figure 2). The most notable
improvement in signs score in group B as
opposed to group A was the reduction of
conjunctivae hyperemia and blepharitis.
TBUT score was basically unaltered by
the therapy. After being asked about
their personal satisfaction of the outcome
of therapy, 80% of patients in group a and
85% of patients in group B felt improve-
ment, 10% and 15% felt no change, and
10% in group A felt worse (Figure 3).
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Fig. 3. Subjective feeling of the outcome of therapy (percentage).
Conclusion
Although small number of patients
enrolled in this study so far renders mak-
ing any firm assumptions unplausible,
the results of using lodoxamide as ad-
juvant therapy in patients with dry eye
encourage further investigation. The most
consistent finding in patients complain-
ing of chronic eye irritation are drasti-
cally low values of TBUT. Although it was
slightly more effective in alleviating
symptoms than lubricant therapy alone,
it appears that lodoxamide was signifi-
cantly more effective in reducing clinical
signs of chronic eye irritation, such are
blepharitis and conjunctivitis.
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LODOXAMID KAO POMO]NA TERAPIJA U BOLESNIKA SA SUHIM
OKOM
S A @ E T A K
Suho oko zbog svoje smanjene funkcije suznog filma postaje osjetljivije na sve oblike
alergena koji se nalaze u zraku. To je zbog zaga|enosti posebno izra`eno u urbanim
sredinama, ~emu pridonosi i na~in `ivota modernog ~ovjeka. Postoje razli~iti uvrije`eni
preparati za lokalnu primjenu koji djeluju na smanjenje alergijske reakcije oka, no
mnogi od njih se moraju ordinirati sa oprezom i samo na kra}a razdoblja zbog poten-
cijalno opasnih nuspojava. Cilj je ovog rada ispitati u~inkovitost lodoksamida, novog
antialergijskog preparata za lokalnu primjenu, ~ija je prednost vrlo mala ili nikakva
mogu}nost nuspojava, u smanjenju lokalnih alergijskih reakcija oka kod pacijenata sa
suhim okom. Istra`ivanje je pokazalo da je u usporedbi sa lije~enjem samo prepara-
tima za rehidraciju oka (umjetne suze), lije~enje sa umjetnim suzama i lodoksamidom
utjecalo na ve}e smanjenje znakova upale, te u manjoj mjeri na smanjenje subjektivnih
smetnji pacijenata.
152
I. Petri~ek et al.: Lodoxamide as Adjuvant Therapy, Coll. Antropol. 25 Suppl. (2001) 149–152
